--- title: "Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY | Sutter Health" description: "A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes" url: "https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY # Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY **Status:** Coming Soon #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668336). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes ## Sub-Investigator [Ulhas M Nadgir, M.D.](https://www.sutterhealth.org/research/investigators/ulhas-m-nadgir-md-2011875488) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Diabetes I or II Sensor GENESIS](https://www.sutterhealth.org/research/clinical-trials/diabetes-i-or-ii-sensor-genesis-2059410607) GENESIS: next GENEration Sensor Life Study **Status:** Open to Enrollment - Clinical trial ### [Diabetes KOS Argus Continuing Glucose Monitoring System](https://www.sutterhealth.org/research/clinical-trials/diabetes-kos-argus-continuing-glucose-monitoring-system-2082984362) Argus 2.0 Adoption Study **Status:** Coming Soon - Clinical trial ### [Diabetes MiniMed™ NMX8-AID System Insulin Pump CIP351 GATEWAY](https://www.sutterhealth.org/research/clinical-trials/diabetes-minimed-nmx8-aid-system-insulin-pump-cip351-gateway-2060811280) GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes **Status:** Open to Enrollment - Clinical trial ### [Type II Diabetes Mellitus ORA-D-013-3](https://www.sutterhealth.org/research/clinical-trials/type-ii-diabetes-mellitus-ora-d-013-3-2068022519) A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on One to Three Glucose-lowering Agents **Status:** Coming Soon - Clinical trial ### [Congenital Adrenal Hyperplasia in Pediatrics CRN04894-13](https://www.sutterhealth.org/research/clinical-trials/congenital-adrenal-hyperplasia-in-pediatrics-crn04894-13-2068022648) A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension **Status:** Coming Soon [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060#medicalwebpage","name":"Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY","description":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes","url":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060","inLanguage":"en-US","dateModified":"2026-09-02","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060#breadcrumblist"}} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060#medicaltrial","name":"Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY","alternateName":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes","url":"https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060","description":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes","identifier":"NCT07668336","code":{"@type":"MedicalCode","codeValue":"NCT07668336","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07668336","status":"https://schema.org/NotYetRecruiting","healthCondition":[{"@type":"MedicalCondition","name":"Diabetes Type 2"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```